Abstract Details

Title A Brain Care Score for Risk of Late-life Depression: Data from the UK Biobank Cohort

Topic General Neurology

Presentation(s) P10 - Poster Session 10 (11:45 AM-12:45 PM)

Poster/Presentation
Number 15-001

Objective Whether or not Brain Care Score (BCS) components are associated with longitudinal changes in mood disorders is not clear. For this study, we tested the hypothesis that the BCS also significantly correlates to late-life depression incidence in the UKB.

Background The 21-point BCS, developed via a modified Delphi process with practitioners and patients, is a novel instrument designed to motivate behavioral and lifestyle changes, ultimately aiming to decrease incidence of dementia and stroke

Design/Methods

The BCS was derived from UKB participants (using both the hospital and general practitioners cohort) aged 40-69 years, at baseline (2006-2010). After excluding patients with prevalent psychiatric disorders, we performed multivariable Cox proportional hazard regression models between the BCS and risk of incident late-life depression, adjusting for sex and stratified by age groups (<50, 50-59, >59 years).

Results

The total BCS (median: 12; IQR:11-14) was derived for 416,370/502,408 (83%) UKB participants with complete data (mean age: 57; females: 54%). After exclusion of 50,395 participants who had mood or psychiatric disorders other than depression, a total of 365,975 participants were included in our analysis. In total, 6,628 incident cases of late-life depression were documented during the median follow-up period of 13 years. Each five-point increase in BCS was associated with a 59% (HR: 0.41, 95% CI: -0.03-0.85) decreased incidence of late-life depression among UKB participants aged <50, 35% (HR: 0.65, 95% CI: 0.57-0.74) among those aged 50-59; and 28% (HR: 0.72, 95% CI: 0.65-0.79) lower risk among those aged >59).

Conclusions

In addition to its associations with dementia and stroke incidence, the BCS strongly correlates with late-life depression incidence in the UK Biobank. Additional research is needed to understand the association between BCS elements and late life depression in additional, diverse cohorts.

Authors/Disclosures
Sanjula D. Singh, MD, PhD PRESENTER	Dr. Singh has nothing to disclose.
Cyprien Rivier, MD (Yale University)	Dr. Rivier has nothing to disclose.
Tin Oreskovic (Big Data Institute, Nuffield Department of Population Health)	No disclosure on file
Sinclair Carr	No disclosure on file
Keren Papier (University of Oxford)	No disclosure on file
Zeina N. Chemali, MD (Massachusetts General Hospital)	Dr. Chemali has nothing to disclose.
Leidys Gutierrez-Martinez, MD (Massachusetts General Hospital)	The institution of Dr. Gutierrez-Martinez has received research support from American Heart Association.
Akashleena Mallick, MD, MBBS (Massachusetts General Hospital- Harvard Medical School)	Dr. Mallick has nothing to disclose.
Livia Parodi	No disclosure on file
Ernst Mayerhofer, MD	Dr. Mayerhofer has nothing to disclose.
Jasper R. Senff, MD (McCance Center for Brain Health)	Dr. Senff has nothing to disclose.
Christina Kourkoulis	No disclosure on file
Sandro Marini, MD (Boston Medical Center)	Dr. Marini has nothing to disclose.
Santiago Clocchiatti-Tuozzo (Yale University, Department of Neurology)	Mr. Clocchiatti-Tuozzo has nothing to disclose.
Courtney Nunley	No disclosure on file
Amy Newhouse (Massachusetts General Hospital)	No disclosure on file
An Ouyang	No disclosure on file
M. B. Westover, MD, PhD (MGH)	Dr. Westover has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Beacon Biosignals. Dr. Westover has stock in Beacon Biosignals. The institution of Dr. Westover has received research support from NIH. Dr. Westover has received publishing royalties from a publication relating to health care. Dr. Westover has a non-compensated relationship as a cofounder with Beacon Biosignals that is relevant to AAN interests or activities.
Ronald M. Lazar, PhD, FAHA, FAAN, FAAN (University of Alabama At Birmingham)	Dr. Lazar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DiaMedica Therapeutics Inc. . The institution of Dr. Lazar has received research support from National Institutes of Health. Dr. Lazar has received publishing royalties from a publication relating to health care.
Aleksandra Pikula, MD	The institution of Dr. Pikula has received research support from CIHR.
Sarah Ibrahim	No disclosure on file
Bart Brouwers (Neurosurgeon Elisabeth-TweeSteden Hospital)	No disclosure on file
Virginia J. Howard, PhD (University of Alabama At Birmingham)	The institution of Dr. Howard has received research support from NIH. The institution of an immediate family member of Dr. Howard has received research support from NIH.
George Howard, PhD (UAB School of Public Hlth)	Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer.
Nirupama Yechoor, MD (MassGeneral Brigham)	Dr. Yechoor has nothing to disclose.
Cornelia Van Duijn (University of Oxford)	No disclosure on file
Thomas Littlejohns (University of Oxford)	No disclosure on file
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care)	Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Jonathan Rosand, MD (Massachusetts General Hospital)	Dr. Rosand has received personal compensation for serving as an employee of Massachusetts General Hospital. Dr. Rosand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Rosand has received research support from NIH. The institution of Dr. Rosand has received research support from American Heart Association. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as a Peer reviewer with National Institutes of Health. Dr. Rosand has a non-compensated relationship as a Trustee with Columbia University that is relevant to AAN interests or activities.
Gregory Fricchione (Massachusetts General Hospital)	No disclosure on file
Christopher D. Anderson, MD, PhD, FAAN (Brigham and Women's Hospital)	The institution of Dr. Anderson has received research support from Bayer AG. The institution of Dr. Anderson has received research support from American Heart Association. The institution of Dr. Anderson has received research support from National Institutes of Health. An immediate family member of Dr. Anderson has received publishing royalties from a publication relating to health care.
Guido J. Falcone, MD (Yale School of Medicine)	The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.

��ɫ��

��ɫ��